Tehran University of Medical Sciences Frontiers in Biomedical Technologies 2345-5837 10 3 2023 06 01 321 326 Mojtaba Rokni Student Research Committee, Babol University of Medical Sciences, Babol, Iran Mehrangiz Amiri Department of Nuclear Medicine, Babol University of Medical Sciences, Babol, Iran Kourosh Ebrahimnejad Gorji Department of Medical Physics Radiobiology and Radiation Protection, School of Medicine, Babol University of Medical Sciences, Babol, Iran Hoda Talebian Department of Medical Physics Radiobiology and Radiation Protection, School of Medicine, Babol University of Medical Sciences, Babol, Iran Ali Bijani Department of Epidemiology, Babol University of Medical Sciences, Babol, Iran Mohsen Vakili Department of Hematology Oncology, Babol University of Medical Sciences, Babol, Iran Hamid Shafiei Department of Psychology, Rajaei Oncology Hospital, Babol University of Medical Sciences, Babol, Iran Fateme Niksirat Department of Medical Physics Radiobiology and Radiation Protection, School of Medicine, Babol University of Medical Sciences, Babol, Iran Meysam Khosravi Department of Medical Physics Radiobiology and Radiation Protection, School of Medicine, Babol University of Medical Sciences, Babol, Iran Ali Shabestani Monfared Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran 2022 08 18 2022 09 04 Purpose: This study aimed to evaluate the effect of samarium-153-EDTMP (153Sm-EDTMP) on pain relief bone metastases of Breast Cancer (BC) and Prostate Cancer (PC) patients. Materials and Methods: Thirty patients aged 40-77 years (62.6±10.2 years) with intractable metastatic bone pain were included in the current study. A checklist of patient information and a standard questionnaire for the assessment of pain and quality of life were completed before and after four and eight week’s palliative treatment with 37 MBq/kg of 153Sm-EDTMP. To analyse the data, parametric and non-parametric tests were used in SPSS software. Results: Twelve females with BC (40%) and 18 males with PC (60%) were included. Four and eight weeks after palliative treatment of 153Sm-EDTMP, the mean pain score reduction and quality of life were statistically increased compared to before the intervention (P-value < 0.05). Notably, the amount of pain reduction in the fourth week was more than in the eighth week; however, the quality of life was better in the eighth week, without significant variation (P-value <0.05). In addition, there was no statistically significant relationship between pain reduction and the type of primary diseases, BC, and PC (P-value >0.05). Conclusion: The injection of 153Sm-EDTMP had therapeutic efficacy for bone pain palliation in patients with diffuse bone metastases at the end of the 4th and 8th week post-infusion. https://fbt.tums.ac.ir/index.php/fbt/article/view/533 https://fbt.tums.ac.ir/index.php/fbt/article/download/533/343